$BCTX is set to showcase major progress at SABCS 2025 with three posters highlighting positive Phase 2, strong biomarker data and momentum in its pivotal Phase 3 study. The Bria-IMT regimen has received Fast Track Designation from US FDA - “Positive clinical data from our Phase 2 study reinforce our confidence in our pivotal Phase 3 study in metastatic breast cancer.” Investors will want this on their radar.

https://globenewswire.com/news-release/2025/1...-2025.html